Nadia Cherradi
  • E-mail :[email]
  • Phone : +33 4 38 78 35 01
  • Location : Grenoble, France
Last update 2018-08-27 19:01:58.869

Nadia Cherradi PhD Molecular and Cellular Biology, CR1 INSERM

Course and current status

After a PhD training in the University Joseph Fourier (Grenoble, France) and a post-doc at the University Hospital of Geneva (Switzerland) focused on the study of the molecular regulation of adrenal steroidogenesis, I have been recruited by INSERM in 2006. Since then,  I lead a research group within the Team “Invasion mechanisms in Angiogenesis and Cancer” (INSERM Unit 1036 Biology of Cancer and Infection) at the Biosciences and Biotechnology Institute of Grenoble (French Atomic Commission CEA) dedicated to the study of post-transcriptional regulation of gene expression by the family of RNA-binding proteins Tristetraprolin and microRNAs in cancer. 

Membership to scientific societies

  • Member of the European Network for the Study of Adrenal Tumors (ENS@T) since 2010.
  • Member of the National Network INCA-COMETE since 2004
  • President and founding member of the association G2L2 (under the french law 1901) (for Grenoble, Genève, Lyon, Lausanne, representing the research groups in Endocrinology, Diabetology and Metabolism of Rhône-Alpes Universities (2008-2013).
  • Member of the French Angiogenesis Society since 2011
  • Member of the French Endocrinology Society since 2004

 

Awards

  • Riotton Pharmaceutical Award (Faculty of Medicine of Geneva, 1997)
  • Mara E. Lieberman Award (Endocrine Society, Toronto, 2000)
  • Searle Young Investigator Award (Aldosterone Conference, Toronto, 2000)
  • Servier Pharmaceutical Award (Swiss Endocrine Society, Bern, 2002)
  • Post-doctoral fellowship from La Ligue Nationale Contre le Cancer (2002-2004)
  • Post-doctoral fellowship from La Fondation de France (2005)
  • Recipient of the INSERM National Research Program in Reproduction and Endocrinology 2007 (PNRRE)
  • Recipient of the INSERM National Program in Translational Research (Contrat Hospitalier de Recherche Translationnelle, 2010-2013).

Scientific summary

A tight link between dysregulations in mRNA decay mechanisms and cancer hallmarks is now clearly established. Notably, abnormal stabilization of transcripts encoding pro-tumoral cytokines, chemokines or proto-oncogenes occurs during tumor development and progression. Our research aims at deciphering the mechanisms involved in such dysregulations and focus on 2 key players in the control of mRNA fate: the Tristetraprolin zinc finger proteins TTP/ZFP36 and Tis11b/ZFP36L1, and microRNAs. We use an integrative approach combining cellular and molecular biology, preclinical models and translational/clinical studies. Our program runs along 3 complementary axes: 1) the study of the molecular mechanisms through which TTP and Tis11b regulates AU-rich elements (ARE)-mediated mRNA decay in normal and cancer cells; 2) the development of preclinical anti-cancer therapies based on multi-target destabilization of ARE-containing transcripts; 3) the search for alterations in mRNA decay regulators (microRNAs and RNA-binding proteins) in adrenocortical cancer and their evaluation as potential diagnostic/prognostic biomarkers and therapeutic targets. 

Image d’exemple